acute myeloid leukemia

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg –– 600 mg determined as…

Pune, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global acute myeloid leukemia market is expected to clock US$ 4.31 billion by 2030 and to grow at a CAGR of 10.2% during the…

New York, USA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape DelveInsight’s relapsed/refractory acute myeloid…

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies,…

Allogeneic hematopoietic cell transplantation (HCT) is appropriate for most older patients with acute myeloid leukemia (AML), experts said, and new research has offered further…

NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many…

The study, co-led by Dr. Philip Awadalla, Senior Principal Investigator and Director, Computational Biology at the Ontario Institute for Cancer Research (OICR) and Dr. Quaid Morris, Member, Computational and Systems Biology, Memorial…

It is reported that only about half of patients with AML achieve long-term disease control. Many others are treated with multi-agent chemotherapy as they fail to respond to initial therapy. ‘Investigational drug – ficlatuzumab (a…

CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive outcome from its preplanned interim…

Treatment outcomes for children, adolescents, and young adults with leukemia have improved dramatically over the last few decades, with a 5-year relative survival rate of 85.3%,…